News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedarplus.ca under the Company’s profile.



Print Version

Resverlogix Closes Equity Offering

Jun 14, 2011

/NOT FOR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES./

TSX Symbol: RVX

CALGARY, June 14, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has closed its previously announced prospectus offering of 7 million units (the "Units") at a price of CDN $1.80 per Unit for gross proceeds of $12.6 million (the "Offering"). Each Unit was comprised of one common share of the Company and one-half of a common share purchase warrant. Each full warrant is exercisable at a price of CDN $2.25 for a period of five years. The offering was co-led by Bloom Burton & Co. and Canaccord Genuity Corp. with Wedbush PacGrow Life Sciences acting as financial advisor in certain jurisdictions outside Canada where it is qualified to carry on business.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: Don@resverlogix.com


Back to News